Breaking News Instant updates and real-time market news.

PFE

Pfizer

$37.53

0.01 (0.03%)

, BABA

Alibaba

$190.03

-0.14 (-0.07%)

08:23
07/14/18
07/14
08:23
07/14/18
08:23

Week in review: How Trump's policies moved stocks

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Trump and his administration with this weekly recap compiled by The Fly: 1. PFIZER: After speaking with President Donald Trump, Pfizer (PFE) stated that it will roll back its July 1 price increases "to give the president an opportunity to work on his blueprint to strengthen the healthcare system and provide more access for patients." This comes after Trump called out the company and other drugmakers for raising prices. In a tweet, the President previously said Pfizer and peers "should be ashamed that they have raised drug prices for no reason," accusing the company and industry of "merely taking advantage of the poor and others unable to defend themselves, while at the same time giving bargain basement prices to other countries in Europe and elsewhere." The same day Pfizer announced the price rollback, the drugmaker said it will reorganize into three units, separating its consumer health-care business, which it has been trying to sell since last year, from its groups focused on "innovative" medicines" and "established" medicines. 2. TRADE WITH CHINA: On Tuesday, the Office of the U.S. Trade Representative released a list of $200B in Chinese goods on which it plans to enact 10% tariffs, escalating a growing trade war with Beijing. The tariffs, which will undergo a two-month review process, are roughly equal to China's exports to the U.S. and some of the products on the list are from sectors of Made in China 2025, a strategic plan to make China a leader in global industries like technology. The move comes after President Donald Trump threatened to implement tariffs on at least $500B on Chinese goods if China retaliated against the $34B in tariffs that went into effect recently. On Wednesday, China's commerce ministry said the proposed U.S. tariffs on the additional $200B of goods are "completely unacceptable" and Beijing will have to respond, Reuters reported. The ministry said the actions taken by the Trump administration hurt America's own interests, China and the rest of the world. Shares of U.S.-listed China technology stocks including Alibaba (BABA), Baidu (BIDU), JD.com (JD), iQIYI (IQ) and Vipshop (VIPS) were under pressure following the news. 3. NEW YORK TIMES: President Donald Trump tweeted on Monday that the "failing NY Times [NYT] Fake News story today about breast feeding must be called out. The U.S. strongly supports breast feeding but we don't believe women should be denied access to formula. Many women need this option because of malnutrition and poverty." 4. PLANET FITNESS: A special panel of the House of Representatives advanced a bipartisan bill on Thursday that would allow taxpayers to claim deductions for gym memberships, fitness classes and other workout expenses to promote a healthy lifestyle. "Americans should have the ability to save and spend their health care dollars the way they want and need," said House Ways and Means Chairman Kevin Brady, according to a report from the Washington Examiner. According to media reports, the legislation would give individuals a $500 allowance on gym memberships and other sports and fitness expenses. Shares of Planet Fitness (PLNT) were higher after the announcement. "Week in Review" is The Fly's weekly recap of its recurring series of "Trump Effect" exclusive stories.

PFE

Pfizer

$37.53

0.01 (0.03%)

BABA

Alibaba

$190.03

-0.14 (-0.07%)

BIDU

Baidu

$267.20

-4.31 (-1.59%)

JD

JD.com

$38.27

-0.25 (-0.65%)

IQ

iQIYI

$33.92

-1.12 (-3.20%)

VIPS

Vipshop

$10.23

-0.09 (-0.87%)

NYT

New York Times

$25.60

-0.6 (-2.29%)

PLNT

Planet Fitness

$48.71

1.2 (2.53%)

  • 22

    Aug

  • 10

    Sep

  • 10

    Sep

PFE Pfizer
$37.53

0.01 (0.03%)

07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
07/11/18
ARGS
07/11/18
NO CHANGE
ARGS
Hold
Pfizer valuation is appropriate, says Argus
Argus analyst David Toung kept his Hold rating on Pfizer, saying the company's valuation at 12.2-times his expected FY19 earnings - below the 12.4-times peer group average for pharmaceutical stocks - is appropriate after its revenue growth slowed in Q1. The analyst notes that higher sales from Eliquis, Ibrance, and Xejanz are being offset by declining sales of drugs faced with a loss of market exclusivity, adding that he remains concerned about competition for Pfizer's key products.
07/11/18
NEED
07/11/18
UPGRADE
Target $5
NEED
Buy
Scynexis upgraded to Buy at Needham after positive phase 2b data for SCY-078
As reported earlier, Needham analyst Alan Carr upgraded Scynexis (SCYX) to Buy from Hold with a price target of $5 after the company's positive Phase 2b trial results of oral SCY-078 in Vulvovaginal Candidiasis. The analyst notes that the data shows the 1-day 300mg BID SCY-078 is "at least equivalent and likely more effective" than the standard 150mg single dose of fluconazole made by Pfizer (PFE). Carr adds that the gastrointestinal tolerability of SCY-078 is also acceptable, which was a key concern in the earlier Phase 2a trial. The analyst further states that the new valuation accounts for expected commercialization of the drug in VVC amid a likely strong interest in a new oral agent suggested by his ObGyn survey last month.
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
BABA Alibaba
$190.03

-0.14 (-0.07%)

07/09/18
DADA
07/09/18
NO CHANGE
Target $8
DADA
Buy
Groupon offers 'tremendous value' in potential sale, says DA Davidson
DA Davidson analyst Tom Forte kept his Buy rating and $8 price target on Groupon following speculation by Recode over the weekend that the company is looking to sell itself. Forte recommends that investors purchase shares, stating that the market is underpricing Groupon as its "North American business has never been in better shape and its international operations are well positioned". In a bull case, the analyst contends that Groupon could be worth $12 per share if it can improve its growth rate or find a strategic buyer where a deal would value the two companies higher than the sum of their parts. Forte speculates about Priceline (PCLN), Alibaba (BABA), Google (GOOGL), and Facebook (FB) as potential acquirers for Groupon.
07/06/18
RHCO
07/06/18
NO CHANGE
Target $215
RHCO
Buy
Alibaba price target lowered to $215 from $235 at SunTrust
SunTrust analyst Youssel Squali lowered his price target on Alibaba to $215, citing the impact of later than expected closing for Ele.me, whose $9.5B acquisition was announced in early April. The analyst is also tempering his expectations for growth in the Cloud segment while noting the adverse impact of the recent USD strength relative to the Renminbi. Longer term, Squali keeps his Buy rating on Alibaba, pointing to "exciting initiatives" around Ant Financial's new funding at $150B, exclusive online broadcasting rights of the World Cup, and promising initiatives around enterprise and voice.
07/06/18
BARD
07/06/18
NO CHANGE
Target $220
BARD
Outperform
Alibaba weakness a buying opportunity, says Baird
Baird analyst Colin Sebastian said the recent weakness in Alibaba is a buying opportunity despite mixed near-term trends. He noted recent data suggests a slight moderation in growth, but he believes several tailwinds, such as the World Cup, will provide a tailwind. He also sees catalysts from further "new retail" and "new logistics" expansion as well as a spotlight on the cloud opportunity. Sebastian reiterated his Outperform rating and $220 price target on Alibaba shares.
07/06/18
SUSQ
07/06/18
NO CHANGE
Target $305
SUSQ
Positive
Alibaba's secular momentum remains strong, says Susquehanna
Susquehanna analyst Shyam Patil said secular momentum remains strong for Alibaba and he sees several years of strong growth ahead. The analyst continues to view the company as a China e-commerce category killer and sees limited downside as multiples are toward the lower end of the historical range. Patil reiterated his Positive rating and $305 price target on Alibaba shares.
BIDU Baidu
$267.20

-4.31 (-1.59%)

07/08/18
FBCO
07/08/18
UPGRADE
FBCO
Outperform
Baidu upgraded to Outperform from Neutral at Credit Suisse
07/09/18
07/09/18
UPGRADE
Target $305

Overweight
Baidu upgraded to Overweight on outlook at KeyBanc
As previously reported, KeyBanc analyst Hans Chung upgraded Baidu to Overweight from Sector Weight, with a $305 price target, based on observations of a change in the prospects for the outlook given a sustainable ramp on news feed ad revenue with daily run rate likely doubling from 30M in Q4 by the end of this year, OCPC model that could drive higher ARPU at advertisers, and the new Phoenix Nest system upgraded with reinforcement learning technology that could drive incremental monetization of search queries and improve conversion rates as well.
07/09/18
07/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. FireEye (FEYE) upgraded to Overweight from Neutral at Piper Jaffray with analyst Andrew Nowinski saying a recent round of channel checks showed a "significant improvement" in demand trends for the company. 2. BP (BP) upgraded to Top Pick from Outperform at RBC Capital with analyst Biraj Borkhataria saying the company's visibility for volume growth will lead to higher cash flows from operations. 3. Capital One (COF) upgraded to Outperform from Perform at Oppenheimer with analyst Ben Chittenden saying the delinquency formation is improving and Q2 expectations seem too low to him. 4. Dunkin' Brands (DNKN) upgraded to Neutral from Underperform at Longbow with analyst Alton Stump saying his conversations with U.S. franchisees lead him to believe the company's Q2 same-store sales rose 0.5-1.0%, which would be in-line with the consensus view and slightly better than his prior forecast for them to have been flat with last year. 5. Baidu (BIDU) upgraded to Outperform from Neutral at Credit Suisse and to Overweight from Sector Weight at KeyBanc. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/09/18
KEYB
07/09/18
UPGRADE
KEYB
Overweight
Baidu upgraded to Overweight from Sector Weight at KeyBanc
JD JD.com
$38.27

-0.25 (-0.65%)

06/19/18
WELS
06/19/18
NO CHANGE
Target $53
WELS
Outperform
JD.com price target raised to $53 from $47 at Wells Fargo
Wells Fargo analyst Ken Sena raised his price target for JD.com (JD) to $53 from $47 after the company and Google (GOOG; GOOGL) announced that the latter will invest $550M in cash in JD.com as part of a strategic partnership. The analyst believes this partnership adds to JD's strong list of existing data and strategic partnerships with Tencent (TCEHY), Walmart (WMT), Baidu (BIDU), Qihoo 360 and Vipshop (VIPS). Sena reiterates an Outperform rating on JD.com shares.
06/15/18
MSCO
06/15/18
NO CHANGE
Target $23
MSCO
Underweight
Etsy fee increase made from position of strength, says Morgan Stanley
Morgan Stanley analyst Brian Nowak said Etsy's (ETSY) planned fee increase is a "smart strategic move from a position of strength" that will bring it into closer alignment with third-party commission rates charged by eBay (EBAY), Amazon (AMZN) and JD.com (JD). While the higher fees will help Etsy invest to attract new buyers, increase marketing and enhance support, Nowak believes the stock's current valuation relative to growth is already pricing in execution and return on these investments, he tells investors. Nowak is reviewing his estimates for Etsy, but currently has an Underweight rating on the stock.
06/14/18
BNPP
06/14/18
INITIATION
Target $44
BNPP
Hold
JD.com initiated with a Hold at BNP Paribas
BNP Paribas initiated JD.com with a Hold and $44 price target.
05/16/18
BNCH
05/16/18
NO CHANGE
Target $19
BNCH
Buy
Vipshop price target lowered to $19 from $24 at Benchmark
Benchmark analyst Fawne Jiang lowered her price target on Vipshop shares to $19 from $24 to reflect a more gradual revenue contribution from the company's partnership with Tencent (TCEHY)and JD.com (JD). Along with the company's Q1 report, Vipshop noted the trial-and-error process and natural learning curve of working with new platforms, leading to its soft Q2 guidance and reservations regarding an accelerated partnership ramp-up, noted Jiang, who keeps a Buy rating on Vipshop shares.
IQ iQIYI
$33.92

-1.12 (-3.20%)

04/25/18
BOFA
04/25/18
INITIATION
Target $21
BOFA
Neutral
iQIYI initiated with a Neutral at BofA/Merrill
BofA/Merrill analyst Eddie Leung initiated iQIYI with a Neutral and $21 price target due to valuation.
05/08/18
GSCO
05/08/18
INITIATION
Target $23
GSCO
Buy
iQIYI initiated with a Buy at Goldman Sachs
Goldman analyst Piyush Mubayi initiated iQIYI with a Buy and $23 price target.
04/24/18
SBSH
04/24/18
INITIATION
Target $22
SBSH
Buy
iQIYI initiated with a Buy at Citi
Citi started iQIYI with a Buy rating and $22 price target.
05/08/18
05/08/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Juniper (JNPR) initiated with a Neutral at Rosenblatt. 2. Nice Systems (NICE) initiated with an Equal Weight at Morgan Stanley. 3. Mersana Therapeutics (MRSN) initiated with an Outperform at Baird. 4. iQIYI (IQ) initiated with a Buy at Goldman Sachs. 5. Cubic (CUB) initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
VIPS Vipshop
$10.23

-0.09 (-0.87%)

06/26/18
LYON
06/26/18
UPGRADE
LYON
Outperform
Vipshop upgraded to Outperform from Underperform at CLSA
CLSA analyst Man Ho Lam upgraded Vipshop to Outperform following recent weakness in shares citing valuation. The analyst believes further downside is limited and sees potential upside from improved cooperation with Tencent-JD in 2H 2018.
07/11/18
GSCO
07/11/18
DOWNGRADE
Target $13.1
GSCO
Neutral
Vipshop downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Ronald Keung downgraded Vipshop to Neutral from Buy citing what he views as "fierce competition" and near-term risk to consensus earnings estimates as management steps up its marketing spending on attracting new users. Given his view that the cost of attracting new users will drag on margins for the coming quarters, Keung lowered his price target on Vipshop shares to $13.10 from $19.20.
05/16/18
05/16/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. 3M (MMM) downgraded to Hold from Buy at Jefferies with analyst Laurence Alexander saying he sees less room for multiple expansion in a rising interest rate environment and feels the risk/reward "looks increasingly challenging at this point." 2. Vipshop (VIPS) downgraded to Sector Weight from Overweight at KeyBanc with analyst Hans Chung saying he sees uncertainties around Tencent (TCEHY) and JD.com (JD) contributions ahead, which drove high expectations for the top-line growth and multiple expansion, and sees margin pressure likely to continue driven by sector competition and the company's hike in marketing expenses to grow new customer organically. 3. PPG (PPG) downgraded to Hold from Buy at Jefferies with analyst Laurence Alexander saying persistent concerns over pricing lagging higher oil-derived raw material costs, end market risk and the reliance on buybacks to protect earnings growth could "easily" move PPG's relative multiple to 10%-15% below the market over the next two years. 4. BT Group (BT) downgraded to Market Perform from Outperform at Bernstein. 5. F5 Networks (FFIV) downgraded to Neutral from Buy at DA Davidson with analyst Mark Kelleher saying the positive factors working in the company's favor, such as its ongoing new iSeries product cycle, high gross margins, strong cash flows, and the application of it security solutions have become increasingly more evident after its last earnings report and have since been reflected in the valuation on the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NYT New York Times
$25.60

-0.6 (-2.29%)

04/30/18
JPMS
04/30/18
UPGRADE
Target $27
JPMS
Overweight
New York Times upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Alexia Quadrani upgraded New York Times to Overweight and raised her price target for the shares to $27 from $25. The analyst believes digital demand will likely drive further "outsized growth" for New York Times. Further, she expects the company's earnings growth to accelerate in early 2019.
04/30/18
04/30/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Altria Group (MO) upgraded to Outperform from Sector Perform at RBC Capital with analyst Nik Modi saying while his concerns around the macro backdrop and fundamentals persist, the current valuation of 13-times forward PE is attractive relative to the broader Consumer Packaged Goods category given the company's potential catalysts of more dividend increases tracking higher interest rates and the FDA approval process for IQOS electronic cigarettes. 2. Aaron's (AAN) upgraded to Buy from Hold at Loop Capital with analyst Anthony Chukumba saying he remains "impressed" by Progressive's revenue growth and thinks the unit will benefit from Rent-A-Center's (RCII) "ongoing struggles." 3. Cirrus Logic (CRUS) upgraded to Buy from Hold at Craig-Hallum with analyst Anthony Stoss saying he believes Apple (AAPL) headwinds are already priced into the stock and a relief rally is likely following the company's upcoming earnings this Wednesday. 4. Ventas (VTR) upgraded to Market Perform from Underperform at BMO Capital with John Kim citing a more attractive valuation after the stock price came down another 19% in 2018. 5. New York Times (NYT) upgraded to Overweight from Neutral at JPMorgan with analyst Alexia Quadrani saying she believes digital demand will likely drive further "outsized growth" for New York Times. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PLNT Planet Fitness
$48.71

1.2 (2.53%)

06/25/18
BARD
06/25/18
NO CHANGE
Target $50
BARD
Outperform
Planet Fitness price target raised to $50 from $45 at Baird
Baird analyst Jonathan Komp raised his price target on Planet Fitness to $50 from $45 based on its bullish long-term outlook on a sizable opportunity, multiple comp drivers, attractive financial model, and addition upside levers. Komp reiterated his Outperform rating on Planet Fitness shares.
06/11/18
COWN
06/11/18
NO CHANGE
Target $50
COWN
Outperform
Planet Fitness price target raised to $50 from $45 at Cowen
Cowen analyst Oliver Chen raised his price target on Planet Fitness to $50 from $45 following meetings with management. The analyst believes its model will sustain growth given its appealing low-price membership, structural demand for health and wellness, high millennial interest, and unit and comp growth. Chen reiterated his Outperform rating on Planet Fitness shares.
06/20/18
BREN
06/20/18
INITIATION
Target $53
BREN
Buy
Planet Fitness initiated with a Buy at Berenberg
Berenberg started Planet Fitness with a Buy rating and $53 price target.
07/11/18
PIPR
07/11/18
NO CHANGE
Target $51
PIPR
Overweight
Planet Fitness price target raised to $51 from $47 at Piper Jaffray
Piper Jaffray analyst Peter Keith raised his price target for Planet Fitness to $51 following the company's announced debt refinance. Importantly, Planet Fitness will likely use an increased cash position to begin repurchasing stock as early as Q4, Keith tells investors in a research note. The analyst finds it reasonable that the company can repurchase $400M-$900M of stock in 2019, or 10%-20% of its market capitalization. He reiterates an Overweight rating on the shares.

TODAY'S FREE FLY STORIES

KKR

KKR

$21.08

-0.75 (-3.44%)

, ACHC

Acadia

$32.05

-0.51 (-1.57%)

06:23
11/20/18
11/20
06:23
11/20/18
06:23
Periodicals
KKR still in talks to buy Acadia Healthcare, NY Post reports »

KKR (KKR) is still deep…

KKR

KKR

$21.08

-0.75 (-3.44%)

ACHC

Acadia

$32.05

-0.51 (-1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVS

CVS Health

$78.54

-0.79 (-1.00%)

, AET

Aetna

$207.68

-1.49 (-0.71%)

06:21
11/20/18
11/20
06:21
11/20/18
06:21
Hot Stocks
CVS Health, Aetna deal expected to close after Thanksgiving holiday »

In connection with the…

CVS

CVS Health

$78.54

-0.79 (-1.00%)

AET

Aetna

$207.68

-1.49 (-0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIEN

Ciena

$32.46

-1.22 (-3.62%)

06:21
11/20/18
11/20
06:21
11/20/18
06:21
Downgrade
Ciena rating change  »

Ciena downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSDT

Helius Medical

06:19
11/20/18
11/20
06:19
11/20/18
06:19
Upgrade
Helius Medical rating change  »

Helius Medical upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QLYS

Qualys

$69.24

-5.355 (-7.18%)

06:19
11/20/18
11/20
06:19
11/20/18
06:19
Upgrade
Qualys rating change  »

Qualys upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 04

    Dec

  • 09

    Jan

NERV

Minerva

$8.32

-0.09 (-1.07%)

06:17
11/20/18
11/20
06:17
11/20/18
06:17
Conference/Events
Minerva management to host key opinion leader breakfast meeting »

Management hosts a Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

INGN

Inogen

$137.57

-4.28 (-3.02%)

06:16
11/20/18
11/20
06:16
11/20/18
06:16
Upgrade
Inogen rating change  »

Inogen upgraded to Strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 04

    Dec

PSTG

Pure Storage

$17.56

-1.56 (-8.16%)

06:15
11/20/18
11/20
06:15
11/20/18
06:15
Recommendations
Pure Storage analyst commentary  »

Pure Storage price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

COWN

Cowen Group

$14.67

-0.38 (-2.52%)

06:14
11/20/18
11/20
06:14
11/20/18
06:14
Conference/Events
Cowen Group to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

GOOG

Alphabet

$1,019.00

-43.01 (-4.05%)

, GOOGL

Alphabet Class A

$1,026.23

-42.9 (-4.01%)

06:13
11/20/18
11/20
06:13
11/20/18
06:13
Periodicals
Google to invest $690M to build new data center in Denmark, Reuters reports »

Google will invest $690M…

GOOG

Alphabet

$1,019.00

-43.01 (-4.05%)

GOOGL

Alphabet Class A

$1,026.23

-42.9 (-4.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Mar

KEG

Key Energy

$8.25

0.02 (0.24%)

06:10
11/20/18
11/20
06:10
11/20/18
06:10
Downgrade
Key Energy rating change  »

Key Energy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$91.34

-1.95 (-2.09%)

06:09
11/20/18
11/20
06:09
11/20/18
06:09
Hot Stocks
Lowe's sees 'positive trends' in FY19 »

Lowe's CEO Marvin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

STXB

Spirit of Texas Bancshares

$19.23

-0.66 (-3.32%)

06:08
11/20/18
11/20
06:08
11/20/18
06:08
Initiation
Spirit of Texas Bancshares initiated  »

Spirit of Texas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$91.34

-1.95 (-2.09%)

06:07
11/20/18
11/20
06:07
11/20/18
06:07
Hot Stocks
Lowe's to exit Mexico retail operations, exploring strategic alternatives »

Management has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

STKS

One Group Hospitality

$2.77

-0.18 (-6.10%)

06:06
11/20/18
11/20
06:06
11/20/18
06:06
Initiation
One Group Hospitality initiated  »

One Group Hospitality…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

LOW

Lowe's

$91.34

-1.95 (-2.09%)

06:04
11/20/18
11/20
06:04
11/20/18
06:04
Earnings
Lowe's sees FY18 adj. EPS $5.08-$5.13, consensus $5.15 »

Sees FY18 revenue up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

CDNS

Cadence Design

$42.78

-2.98 (-6.51%)

, SNPS

Synopsys

$85.72

-4.37 (-4.85%)

06:04
11/20/18
11/20
06:04
11/20/18
06:04
Initiation
Cadence Design, Synopsys initiated  »

Cadence Design initiated…

CDNS

Cadence Design

$42.78

-2.98 (-6.51%)

SNPS

Synopsys

$85.72

-4.37 (-4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 04

    Dec

  • 05

    Dec

  • 13

    Dec

  • 12

    Mar

KW

Kennedy Wilson

$18.63

-0.2 (-1.06%)

06:03
11/20/18
11/20
06:03
11/20/18
06:03
Hot Stocks
Kennedy Wilson signs two lease deals in Europe with WeWork and ASOS »

Kennedy Wilson has signed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$91.34

-1.95 (-2.09%)

06:02
11/20/18
11/20
06:02
11/20/18
06:02
Earnings
Lowe's reports Q3 adj. EPS $1.04, consensus 98c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

SNPS

Synopsys

$85.72

-4.37 (-4.85%)

06:02
11/20/18
11/20
06:02
11/20/18
06:02
Initiation
Synopsys initiated  »

Synopsys initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 13

    Dec

CYAD

Celyad

$26.97

(0.00%)

06:00
11/20/18
11/20
06:00
11/20/18
06:00
Conference/Events
Celyad management to meet with William Blair »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 22

    Nov

  • 27

    Nov

  • 01

    Dec

  • 03

    Dec

  • 10

    Dec

CSII

Cardiovascular Systems

$28.79

-1.7 (-5.58%)

05:59
11/20/18
11/20
05:59
11/20/18
05:59
Conference/Events
Cardiovascular Systems management to meet with William Blair »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

MDGL

Madrigal Pharmaceuticals

$120.49

-8.98 (-6.94%)

05:57
11/20/18
11/20
05:57
11/20/18
05:57
Conference/Events
Madrigal Pharmaceuticals management to meet with JMP Securities »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

MCD

McDonald's

$186.69

-0.96 (-0.51%)

05:54
11/20/18
11/20
05:54
11/20/18
05:54
Conference/Events
McDonald's management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

KEX

Kirby

$74.67

-1.225 (-1.61%)

05:51
11/20/18
11/20
05:51
11/20/18
05:51
Conference/Events
Kirby management to meet with Seaport Global »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.